Thymosin beta-4 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Calculated for the acetylated heptapeptide |
| Molecular weight | ~889 Da | Monoisotopic mass approximately 889.0 Da |
| Amino acid sequence | Ac-LKKTETQ | N-terminal acetylated seven-residue peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid |
| Solubility class | Water-soluble | Peptides of this size generally dissolve in aqueous media |
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
After a few attempts, he produced a model with physically plausible hydrogen bonds. Pauling then worked with Corey and Branson to confirm his model before publication. In 1954, Pauling was awarded his first Nobel Prize "for his research into the nature of the chemical bond and its application to the elucidation of the structure of complex substances" (such as proteins), prominently including the structure of the α-helix.
Most frequently seen, however, is the eastern or red-spotted newt (Notophthalmus viridescens), whose terrestrial eft form is often encountered on the open, dry forest floor. It has been estimated that salamanders represent the largest class of animal biomass in the Appalachian forests. Frogs and toads are of lesser diversity and abundance, but the wood frog (Rana sylvatica) is, like the eft, commonly encountered on the dry forest floor, while a number of species of small frogs, such as spring peepers (Pseudacris crucifer), enliven the forest with their calls. Salamanders and other amphibians contribute greatly to nutrient cycling through their consumption of small life forms on the forest floor and in aquatic habitats. Although reptiles are less abundant and diverse than amphibians, a number of snakes are conspicuous members of the fauna. One of the largest is the non-venomous black rat snake (Elaphe obsoleta obsoleta), while the common garter snake (Thamnophis sirtalis) is among the smallest but most abundant. The eastern copperhead (Agkistrodon contortrix) and the timber rattler (Crotalus horridus) are venomous pit vipers. There are few lizards, but the broad-headed skink (Eumeces laticeps), at up to 13 in (33 cm) in length, and an excellent climber and swimmer, is one of the largest and most spectacular in appearance and action. The most common turtle is the eastern box turtle (Terrapene carolina carolina), which is found in both upland and lowland forests in the central and southern Appalachians.
== Obesity == The British medical journal, Lancet, published a study examining trends in mean body mass index (BMI) for adults in all countries. Obesity was defined as a BMI score greater than 30. Age standardized obesity rates in 2014, broken down by country and gender were extracted from these data. Included were all countries with a population of 10 million or more. Thailand ranked 34 of the top 55 countries (of 200 countries total irrespective of population) (1=most obese). Other ASEAN nations ranked were Malaysia, 32; Indonesia, 41; Philippines, 42; Myanmar, 48; Vietnam, 55. In all ASEAN nations listed, the rate of female obesity exceeded that of males.
Sources: en.wikipedia.org
In 2010, Tetra Pak reported a 5.2 percent increase in sales, with an annual turnover of approximately €10 billion. Growth in Asian, Eastern European, and South American markets helped drive the increase. The company opened a €120 million aseptic packaging plant in Vietnam in 2019 to supply countries in the Association of Southeast Asian Nations, Australia, and New Zealand. According to the company, it had total sales of €11.5 billion in 2019. Tetra Pak's most popular product is the Tetra Brik Aseptic, a best-seller since the 1970s.
=== Other work === In the initial years of his research, King focused on fundamental mechanisms of mass transfer between gases and liquids. This applied to separation processes such as absorption and distillation. Some of his other work dealt with systematic methods for synthesizing processes from component steps, such as sequencing multiple distillation columns and cascade refrigeration systems. King stopped chemical engineering research in 1999, part-way through his service as Provost and Sr. Vice President for the University of California, university-wide. When he returned in 2004 to be director of Berkeley's Center for Studies in Higher Education, he wrote a number of papers relating to university structure, function, and governance and then the book on the University of California.
=== Fruit === The tulip's fruit is a globose or ellipsoid capsule with a leathery covering and an ellipsoid to globe shape. Each capsule contains numerous flat, disc-shaped seeds in two rows per chamber. These light to dark brown seeds have very thin seed coats and endosperm that do not normally fill the entire seed.
Maternal behavior: Female rats given oxytocin antagonists after giving birth do not exhibit typical maternal behavior. By contrast, virgin female sheep show maternal behavior toward foreign lambs upon cerebrospinal fluid infusion of oxytocin, which they would not do otherwise. Oxytocin is involved in the initiation of human maternal behavior, not its maintenance; for example, it is higher in mothers after they interact with unfamiliar children rather than their own. Human ingroup bonding: Oxytocin can increase positive attitudes, such as bonding, toward individuals classified as "in-group" members, whereas other individuals become classified as "out-group" members. Oxytocin has also been implicated in lying when lying would prove beneficial to other in-group members. In a study where such a relationship was examined, it was found that when individuals were administered oxytocin, rates of dishonesty in the participants' responses increased for their in-group members when a beneficial outcome for their group was expected. Both of these examples show the tendency of individuals to act in ways that benefit those considered to be members of their social group, or in-group. Decreased oxytocin and receptor expression has been associated with aggressive behavior in aggressive-impulsive disorders. Oxytocin is not only correlated with individuals' preferences to associate with members of their own group, but it is also evident during conflicts between members of different groups.
Sources: en.wikipedia.org
The two substrates of this enzyme are cyclopentanol and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are cyclopentanone, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is cyclopentanol:NAD+ oxidoreductase.
=== Treatment === The US CDC reports no specific antidote for azide poisoning. A 2021 narrative review identifies several cases of survival from ingestion when the patient is treated with antidotes for cyanide poisoning. From a mechanistic standpoint, hydroxocobalamin is more likely to be helpful than other antidotes such as sodium nitrite and sodium thiosulfate. As a result, the recommended treatment is hemodynamic support and hydroxocobalamin. First responders should use personal protection equipment to protect themselves from azide exposure.
Psilocybin is dephosphorylated into its active form psilocin in the body and hence is a prodrug. Psilocybin is metabolized in the intestines, liver, kidneys, blood, and other tissues and bodily fluids. There is significant first-pass metabolism of psilocybin and psilocin with oral administration. No psilocybin has been detected in the blood in humans after oral administration, suggesting virtually complete dephosphorylation into psilocin with the first pass. It is also said to be converted 90% to 97% into psilocin. The competitive phosphatase inhibitor β-glycerolphosphate, which inhibits psilocybin dephosphorylation, greatly attenuates the behavioral effects of psilocybin in rodents. Psilocybin undergoes dephosphorylation into psilocin via the acidic environment of the stomach or the actions of alkaline phosphatase (ALP) and non-specific esterases in tissues and fluids. Psilocin is demethylated and oxidatively deaminated by monoamine oxidase (MAO), specifically monoamine oxidase A (MAO-A), into 4-hydroxyindole-3-acetaldehyde (4-HIAL or 4-HIA). 4-HIAL is then further oxidated into 4-hydroxyindole-3-acetic acid (4-HIAA) by aldehyde dehydrogenase (ALDH) or into 4-hydroxytryptophol (4-HTOL or 4-HTP) by alcohol dehydrogenase (ALD). Deamination of psilocin by MAO-A appears to be responsible for about 4% or 33% of its metabolism in different studies. In contrast to psilocin, its metabolites 4-HIAA and 4-HTP showed no affinity for or activation of multiple serotonin receptors and are considered inactive.
Sources: en.wikipedia.org
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.
No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.
It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.